WS Investor
18 Nov 2026, 09:09
Gilead Expands Ebola Access Strategy Through Voluntary Licensing
Gilead Sciences (NASDAQ: GILD) signed royalty-free voluntary licensing agreements with Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease.
The agreements cover 127 primarily low- and lower-middle-income countries and are intended to support manufacturing readiness, technology transfer and supply planning while the Phase 3 EBO-PEP trial evaluates obeldesivir as post-exposure prophylaxis.
Gilead is also expanding existing voluntary licensing agreements for remdesivir to include filovirus disease, contingent on clinical results and potential regulatory approvals. The company has already donated more than 38,000 vials of remdesivir across the Democratic Republic of the Congo, Uganda and Kenya as part of its outbreak-response efforts.
The move strengthens Gilead’s preparedness and global-access strategy for emerging infectious diseases, although neither obeldesivir nor remdesivir is currently approved for Ebola Bundibugyo treatment or prevention.
Gilead Sciences (NASDAQ: GILD) signed royalty-free voluntary licensing agreements with Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease.
The agreements cover 127 primarily low- and lower-middle-income countries and are intended to support manufacturing readiness, technology transfer and supply planning while the Phase 3 EBO-PEP trial evaluates obeldesivir as post-exposure prophylaxis.
Gilead is also expanding existing voluntary licensing agreements for remdesivir to include filovirus disease, contingent on clinical results and potential regulatory approvals. The company has already donated more than 38,000 vials of remdesivir across the Democratic Republic of the Congo, Uganda and Kenya as part of its outbreak-response efforts.
The move strengthens Gilead’s preparedness and global-access strategy for emerging infectious diseases, although neither obeldesivir nor remdesivir is currently approved for Ebola Bundibugyo treatment or prevention.